Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 20, 2026, 9:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the local directory fallback.
Local D1 index available.
Filters: Condition: Insulin-like Growth Factor-1 Deficiency Clear all
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Insulin-like Growth Factor-1 Deficiency
Interventions
Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]), NutropinAq® (Somatropin [rDNA origin])
Drug
Lead sponsor
Ipsen
Industry
Eligibility
5 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced May 20, 2026, 9:07 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Primary Insulin-like Growth Factor-1 Deficiency
Interventions
mecasermin [rDNA origin] injection
Biological
Lead sponsor
Ipsen
Industry
Eligibility
Not listed
Enrollment
1,378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced May 20, 2026, 9:07 AM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Interventions
rhIGF-1 (mecasermin) for a period of 86 weeks
Drug
Lead sponsor
Ipsen
Industry
Eligibility
3 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced May 20, 2026, 9:07 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Interventions
rhIGF-1 (mecasermin, Tercica, Inc.)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
3 Years to 12 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced May 20, 2026, 9:07 AM EDT